Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pathway receives FDA acceptance for filing cancer drug IND
The FDA’s decision allows the company to start a Phase 1 clinical trial of PWT33597, a proprietary, selective, dual inhibitor of PI3K kinase alpha and mTOR. The Phase
The FDA’s decision allows the company to start a Phase 1 clinical trial of PWT33597, a proprietary, selective, dual inhibitor of PI3K kinase alpha and mTOR. The Phase
Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma. The study evaluated the safety and efficacy of avanafil as a treatment of
Under the agreement, Gallus is acquiring several Xcellerex bioproduction systems for new suites and laboratories at its existing manufacturing facility. The strategic collaboration will provide Gallus with manufacturing
The company expects to enroll around 110 healthy subjects. The study expects to evaluate whether Matrix M is safe and improves the effect on elderly people, due to
CEN-209 is selectively activated in areas of low oxygen often found within solid tumors. Auckland Cancer Society Research Centre (ACSRC) professor William Wilson and associate professor Michael Hay,
The lawsuit was filed in connection with Glenmark‘s submission of an abbreviated new drug application (ANDA) for 0.1% hydrocortisone butyrate cream, Glenmark’s generic version of Locoid Lipocream. As
In the study, the patients will be randomized to either certolizumab pegol plus methotrexate (MTX) or adalimumab plus MTX for 12 weeks. Following this, the patients who will
ACZ885 is an investigational fully human monoclonal antibody that inhibits interleukin-1 beta (IL-1 beta), which is part of the body’s immune system defenses. ACZ885 works by neutralizing IL-1
According to the agreement, Elan will become an approximate 24% shareholder in Proteostasis. Elan will be eligible for licensing compounds that will be developed under the pact. As
Piperacillin and tazobactam for injection, the generic version of Zosyn, is indicated to treat patients with moderate to severe bacterial infections. Piperacillin is a penicillin antibiotic that fights